赛诺菲-安万特 SNY 深 沪
已收盘 02-06 16:00:00 美东时间
47.83
+0.340
+0.72%
华盛通- 最 高47.95
- 今 开47.46
- 成交量 386.73万股
- 最 低 47.3479
- 昨 收 47.49
- 总市值 1155.23亿
- 52周最高 58.5164
- 市盈率 静 19.98
- 换手率 0.16%
- 52周最低 44.6168
- 委 比 -97.45%
- 总股本 24.15亿
- 历史最高 58.5164
- 量 比 0.78
- 振 幅 1.27%
- 历史最低 15.4368
- 每 手 1
- 风险率 2.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多突发！赛诺菲疫苗中国首席业务官离职
（来源：CHC医疗传媒） 文章参考：罗湿兄 赛诺菲疫苗中国首席业务官，负责全国所有产品的业务推广的张明峰女士将离职，最后工作日为2026年2月28。 公开资料...
02-05 15:31
BUZZ-Perspective Therapeutics jumps after $175 mln equity offering
BUZZ-Perspective Therapeutics jumps after $175 mln equity offering ** Radiation oncology firm Perspective Therapeutics CATX.A shares up 17.3% at $4.44 on Mon after $175 mln follow-on offering ** CATX early Mon announced pricing 46.2 mln shares, including ~6.6 mln pre-funded warrants, at $3.79, in li
02-02 23:34
赛诺菲遗传性疾病药物后期临床试验结果喜忧参半
法国制药企业赛诺菲 2 月 2 日宣布，其一款试验性遗传性疾病治疗药物，在针对特定类型戈谢病患者的后期临床试验中展现出治疗潜力，但在另一项针对法布里病的临床...
02-02 17:09
Sanofi graft-versus-host disease asset Rezurock gains EU approval recommendation
The European Medicine Association's Committee for Medicinal Products for Human Use has given a positive recommendation for conditional approval to Sanofi's (SNY) chronic graft-versus-host disease trea...
01-30 21:51
Regeneron posts Q4 beat as Sanofi collaboration offsets Eylea headwinds
Regeneron (REGN) reported better-than-expected Q4 2025 financials on Friday as an improvement in collaboration revenue tied to its Sanofi (SNY) partnership offset a sales decline for its blockbuster e...
01-30 20:07
FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms
FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms Changes dateline, adds Eli Lilly details in paragraph 11 Jan 30 (Reuters) - Global drugmakers are ramping up U.S. manufacturing and stockpiling inventory as the Trump administration considers a 100% tariff on imported branded
01-30 20:07
Regeneron Pharma Q4 adjusted EPS beats estimates on demand for Dupixent, EYLEA
Regeneron Pharma Q4 adjusted EPS beats estimates on demand for Dupixent, EYLEA Overview Biotechnology firm's Q4 revenue rose 3%, beating analyst expectations Adjusted EPS for Q4 beat analyst expectations Company announced FDA approvals for EYLEA HD and Libtayo Outlook Regeneron expects 2026 GAAP R&D
01-30 19:42
罗氏、赛诺菲业绩表现平淡，药企巨头加码管线研发提振市场信心
专题：聚焦美股2025年第四季度财报 核心要点 制药企业罗氏与赛诺菲发布的全年业绩符合市场预期，未能推动两家公司股价出现明显波动。 面对...
01-29 23:35
Sanofi Warns Dupixent Is Too Big To Replace As Patent Clock Ticks
Sanofi SA (NASDAQ: SNY) reported Q4 sales of $13.159B, missing consensus of $13.41B. CEO expects profitable growth to continue over 5 years.
01-29 20:08
